Care Gaps and System Issues With Delivering Cardiovascular Risk Reduction and Lipid-Lowering Therapy in Secondary...

Area of Science:

• Cardiology
• Clinical Practice
• Public Health

Background:

• Significant care gaps exist in lipid-lowering therapy for atherosclerotic cardiovascular disease (ASCVD).
• Challenges in lipid management persist, particularly after percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS).
• Discrepancies noted between recommended guidelines and actual clinical implementation of lipid-lowering treatments.

Purpose of the Study:

• To examine care gaps in lipid-lowering therapy for ASCVD patients.
• To identify challenges in lipid management post-PCI and ACS.
• To evaluate the effectiveness of interventions in improving lipid management outcomes.

Main Methods:

• Review of studies focusing on lipid testing and treatment adequacy post-PCI and ACS.
• Analysis of knowledge and practice gaps among primary care practitioners regarding lipid guidelines.
• Evaluation of initiatives like GOAL Canada and ACS Reflective III Pilot.

Main Results:

• Identified gaps in lipid testing and treatment adequacy following PCI and ACS.
• Demonstrated improvements in nonstatin therapy uptake and LDL cholesterol target achievement through educational interventions.
• Highlighted persistent systemic challenges in drug approval and reimbursement affecting newer agent accessibility.

Conclusions:

• Targeted educational interventions can improve lipid management outcomes in high-risk ASCVD populations.
• These interventions show potential to positively influence clinical practice.
• Addressing systemic barriers is crucial for enhancing access to advanced lipid-lowering therapies.